# Trade Execution Log

**Model:** Perplexity
**Date:** 2026-01-27

```text

==================================================
üìä ALPACA PRE-FLIGHT STATUS (Perplexity)
==================================================
üí∞ Equity: $1,027.54
üí∏ Buying Power: $819.17

üìÇ Current Positions:
   ‚Ä¢ IBRX: 4 shares @ $6.18 (Current: $5.61)
   ‚Ä¢ NTLA: 3 shares @ $14.24 (Current: $15.37)
   ‚Ä¢ VERA: 3 shares @ $45.72 (Current: $46.60)

üìù Open Orders:
   ‚Ä¢ NTLA: LIMIT SELL 3 shares @ $22.00 (new)
   ‚Ä¢ NTLA: STOP SELL 3 shares Stop @ $10.75 (OCO-held)
   ‚Ä¢ VERA: STOP SELL 3 shares Stop @ $42.84 (OCO-held)
   ‚Ä¢ IBRX: STOP SELL 4 shares Stop @ $5.50 (OCO-held)
   ‚Ä¢ IBRX: LIMIT SELL 4 shares @ $14.02 (new)
   ‚Ä¢ VERA: LIMIT SELL 3 shares @ $55.53 (new)

==================================================

üìã Parsing Portfolio Recommendation from Clipboard...
--------------------
üìã CLIPBOARD CONTENT:
| ACTION | TICKER | QTY | TYPE  | LIMIT_PRICE | STOP_LOSS | TAKE_PROFIT | REASON                                                                                                                                                                                |
| ------ | ------ | --- | ----- | ----------- | --------- | ----------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| HOLD   | IBRX   | 4   | N/A   | N/A         | 2.74      | N/A         | Maintain position: trend above 20/50 SMA, multiple positive ANKTIVA data points and regulatory paths, no major negative news; technical invalidation set just below 50SMA.            |
| HOLD   | NTLA   | 3   | N/A   | N/A         | 9.72      | N/A         | Maintain position: FDA lifted MAGNITUDE-2 hold, late-stage pipeline and 2026 catalysts intact despite residual MAGNITUDE risk; stop placed just below 50SMA as uptrend invalidation.  |
| HOLD   | VERA   | 3   | N/A   | N/A         | 42.2      | N/A         | Maintain position into Priority Review / PDUFA July 7, 2026; stock above 50SMA with intact IgAN thesis and strong analyst support, so stop set slightly below 50SMA.                  |
| BUY    | RUN    | 12  | LIMIT | 19.5        | 18.3      | 21.9        | High-short-interest squeeze setup: ~28%+ short-of-float, price above 20/50/200 SMAs, Q4 earnings catalyst around Feb 25‚Äì26, 2026; position sized to risk ‚â§15.45 with ‚â•2R take-profit. |
--------------------

üîé Found 5 trade(s) (Markdown table).

üõ°Ô∏è SYNCING PROTECTION: IBRX (Target Stop: $2.74)
   üîÑ Updating: Found stop @ $5.50 (held). Replacing with $2.74
   ‚úÖ SUCCESS: Stop-loss update requested for IBRX.

üõ°Ô∏è SYNCING PROTECTION: NTLA (Target Stop: $9.72)
   üîÑ Updating: Found stop @ $10.75 (held). Replacing with $9.72
   ‚úÖ SUCCESS: Stop-loss update requested for NTLA.

üõ°Ô∏è SYNCING PROTECTION: VERA (Target Stop: $42.20)
   üîÑ Updating: Found stop @ $42.84 (held). Replacing with $42.20
   ‚úÖ SUCCESS: Stop-loss update requested for VERA.

üöÄ PROCESSING BUY: RUN
   Order: BUY 12 RUN @ $19.50 (SL: $18.30, TP: $21.90) (Est. Cost: $234.00)
   ‚úÖ SUCCESS: Buy order placed!
```
